Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Canaccord 45th Annual Growth Conference 2025
33 slides from Imricor Medical Systems's conference presentation, Aug 13, 2025
Slide 1: Canaccord 45th Annual Growth Conference - Boston
For personal use only Canaccord 45 th Annual Growth Conference - Boston Augus t 2025 Imricor's vision is to bring iCMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Cardiac Arrhythmias – A growing problem globally
Cardiac Arrhythmias – A growing problem globally Disturbances in the electrical impulses that maintain For personal use only a regular heart rhythm causes arrhythmias, that largely present as: • atrial flutter (AFL) • atrial fibrillation (Afib) • ventricular tachycardia (VT) Arrhythmias are a leadin
Slide 3: Treatment options
Treatment options 1 Ablation For personal use only • Catheter ablations have become first-line therapy for curing arrhythmias • Ablations can permanently restore the heart to normal rhythm • Minimally invasive surgery where a catheter is guided into the heart and energy is applied to destroy the hea
Slide 4: Catheter Ablation
Catheter Ablation For personal use only A catheter is guided into the heart and the physician will apply energy (radiofrequency, cryo, pulse field) through the catheter with the purpose of forming scars/lesions that destroy the heart cells responsible for causing the electrical misfiring. If the rig
Slide 5: X-Ray as an imaging modality
X-Ray as an imaging modality For personal use only X-rays are particularly good for visualizing bones and detecting fractures, dislocations, and bone density issues LIMITATIONS Soft Tissue Visualization X-rays are not as effective at visualizing soft tissues like muscles, ligaments, and organs. Radi
Slide 6: X-Ray guided cardiac ablation in conventional EP Lab
X-Ray guided cardiac ablation in conventional EP Lab In the past, doctors had to rely on X-Ray guidance as the only imaging modality available For personal use only CHALLENGES OF X-RAY Cannot visualize soft Cannot confirm lesions tissue of the heart created are durable Drives additional tool usage l
Slide 7: MRI as an imaging modality
MRI as an imaging modality For personal use only MRI is highly sensitive in detecting a variety of conditions, including tumours, brain disorders, spinal cord injuries, joint abnormalities, and vascular diseases. Detail MRI provides excellent contrast between different types of soft tissues, making
Slide 8: The Promise of MRI for Cardiac Interventions
The Promise of MRI for Cardiac Interventions Researchers from Johns Hopkins in the 1990’s and 2000’s demonstrated the benefits of performing ablations under MRI instead of X-Ray guidance. For personal use only The promise was for faster procedures, lower costs, higher first-time success rates all in
Slide 9: Imricor has pioneered this new approach over years
Imricor has pioneered this new approach over 19 years BENEFITS OF MRI For personal use only Superior soft tissue Lower cost, no need for ICE visualization in 3D catheter to guide septal crossing Faster procedures, no need Lower overall cost burden to map out the heart with on health system and expen
Slide 10: Imricor Enable Modern iCMR Labs
Imricor Enable Modern iCMR Labs • Imricor captures 100% of the consumable catheter revenue for each procedure For personal use only Capital equipment (Advantage-MR, 3rd party equip) Imricor iCMR lab (MRI scanner and lab room) Consumables MRI Partners (catheters, etc.) Siemens Philips Imricor GE Soft
Slide 11: Modern iCMR Lab Vendors
Modern iCMR Lab Vendors MRI COMPATIBLE EQUIPMENT NEEDED DEVELOPER IMRICOR REVENUE TYPE Ablation catheter Imricor Consumable For personal use only Diagnostic catheter Imricor Consumable Transseptal puncture kit Imricor Consumable Dispersive electrode Imricor Consumable Various sterile cables Imricor
Slide 12: For personal use only
For personal use only “What may have taken several hours in the x-ray lab took less than an hour to perform using NorthStar in the iCMR” DR. MARCO GÖTTE Amsterdam University Medical Center Ca naccord Growth Conference - Bos ton | 12 Investor Presentation, CaSeptember 2021 - Bos ton | 12 naccord Grow
Slide 13: Market Opportunity
For personal use only Market Opportunity
Slide 14: iCMR Lab Economics
iCMR Lab Economics: For personal use only Hospital Labs X-ray and iCMR labs cost about the same to build: $3 million1 Procedures Procedure costs X-ray Lab iCMR Lab Annual benefit for iCMR3 AFL device costs $4,443 $4,000 $44,430 / yr VT device costs $9,618 $6,500 $311,800 / yr Afib device costs4 $9,6
Slide 15: iCMR Lab Economics: US Top Hospitals by volume
iCMR Lab Economics: US Top 50 Hospitals by volume AFL VT Afib Total Average procedures pa 434 173 1010 1617 For personal use only Imricor Imricor ASP US$ per procedure $4000 $6500 $6500 Revenue opportunity per hospital US$ $1.7m $1.1m $6.6m $9.43m Total Potential ATRIAL FLUTTER VT AFIB Revenue per H
Slide 16: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers For personal use only Electrophysiology Devices Market Size US$bn DRIVERS OF GLOBAL CATHETER 40 ABLATION MARKET 35 15% CAGR Increased incidence of 30 ca
Slide 17: Imricor today
Imricor today • Commercial in Europe for Atrial Flutter • VISABL-VT trial to expand indications under way For personal use only • Commercial in Middle East with final product registrations • Imricor’s products are currently imminent approved in 31 countries, with 8 • Growing pipeline of new hospital
Slide 18: Imricor Regulatory Status
Imricor Regulatory Status Imricor Product Suite Approved Status Comment For personal use only • NorthStar • Advantage-MR EP Recorder/Stimulator • Full technology platform to perform • Vision-MR Diagnostic Catheter real-time iCMR guided atrial flutter Europe CE Mark • • Vision-MR Diagnostic Cable Vis
Slide 19: Looking Ahead to 2025
Looking Ahead to 2025 For personal use only
Slide 20: Several key value drivers during 2025/26
Several key value drivers during 2025/26 For personal use only FDA Approval for US commercial release of platform technology • 510(k) submissions / approvals • VISABL-AFL clinical trial • PMA submissions / approvals Expanding VT ablation guided by MRI • VISABL-VT clinical trial, AUMC currently enrol
Slide 21: Questions?
For personal use only Questions?
Slide 22: Appendix
For personal use only Appendix
Slide 23: NorthStar – Approved in Europe, submitted for approval in the US
NorthStar – Approved in Europe, submitted for approval in the US For personal use only Key piece of the infrastructure, intended to be the central hub of every iCMR lab NorthStar Application potential well beyond cardiac ablation Strong in-bound interest from hospitals Solves problem for pediatric h
Slide 24: The problems we are solving through MRI-guided ablation procedures
The problems we are solving through MRI-guided ablation procedures VISUALISATION PROCEDURE COST PROCEDURE SAFETY only EFFECTIVENESS TIME • X-ray imaging provides • Visualisation limitations • Higher overall medical • Conventional 3D • Patient and doctor poor heart visualisation lead to reduced singl
Slide 25: Partners, Hospitals we Provide into and KOL Validation
Partners, Hospitals we Provide into and KOL Validation Our Partners PROF. GERHARD HINDRICKS DR. MARCO GÖTTE German Heart Center Amsterdam University of the Charité Medical Center For personal use only “With MRI-guided treatment of heart conditions, we are working “We are extremely excited to towards
Slide 26: A strong intellectual property portfolio
A strong intellectual property portfolio Imricor’s patents protect technology that allows Imricor to For personal use only manufacture medical devices that are uniquely MRI compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor. 21 is
Slide 27: FDA Global Pivotal Trial
FDA Global Pivotal Trial VISABL-AFL Trial – FDA Approval pathway Trial details For personal use only • Treatment of type 1 atrial flutter • Patients : 91 • Participating hospitals : 4 • Expected FDA approval of PMA : 2H 2026 • Comment: Regulatory review process already underway, review of clinical t
Slide 28: MRI guided VT ablation - the most significant event in Imricor's history
For personal use only MRI guided VT ablation - the most significant event in Imricor's history VISABL-VT Trial – CE Mark Approval Pathway for 2 nd Indication Trial details • Treatment of Ventricular Tachycardia • Patients : 64 • Participating hospitals : 2 • Comment: Trial data expected to stimulate
Slide 29: Imricor's Pipeline of Leading Tools for iCMR Labs
Imricor’s Pipeline of Leading Tools for iCMR Labs Current Products Future Products Our iCMR family of products are designed with patented technology to Products are developed and going through meet the needs of physicians and CVD patients around the world For personal use only approvals to expand in
Slide 30: Key Terms
Key Terms Vision-MR Ablation • Medical device developed by Imricor, designed for use within an MRI Catheter • World first, no competitors, all others only compatible with X-ray For personal use only • Irregular heartbeat, affects approximately 2% of US population • Expected to double to 4% of US pop
Slide 31: Imricor Leadership: Management
Imricor Leadership: Management For personal use only STEVE WEDAN JONATHON GUT GREGG STENZEL NICK CORKILL NICK TWOHY President and Chief Executive Officer, Vice President of Finance and Chief Chief Operating Officer Vice President Vice President of Marketing and Board Chair Financial Officer Corporat
Slide 32: Imricor Leadership: Board of Directors
Imricor Leadership: Board of Directors For personal use only STEVE WEDAN MARK TIBBLES PETER MCGREGOR ANITA MESSAL Jeffrey Leighton President and Chief Executive Deputy Chair and Lead Non-executive Director Non-executive Director Non-executive Director Officer, and Board Chair Independent Director Dr
Slide 33: Contact Information
Contact Information Investors & Australian Media: For personal use only Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.c
Imricor Medical Systems — Canaccord 45th Annual Growth Conference 2025 on 6ix